Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (13517)	1/20/1998 11:36:00 AM
From: Henry Niman	Respond to of 32384

Bernie, I have added a synopsis to Kevin Wilson's analysis (under SBH and AHP aalliances). I looks like someone is sending out Links to LGND's address. The site ( home.att.net ) is getting hit so hard that I'm having trouble keeping up. (It has been hit almost 500 times this morning and you can pretty much guess who the heavy hitters are).

To: Flagrante Delictu who wrote (13517)	1/20/1998 11:51:00 AM
From: Andrew H	Read Replies (5) \| Respond to of 32384

Hey Bernie, welcome back from H and Q and to SI. >>At the breakout session after the LGND presentation at H&Q, Dr. Steven Reich seemed to indicate that LGND would be going forward in the areas of NSCLC, prostate, ovarian, & breast cancer.<< That sounds like unexpectedly good news. With the prostate, ovarian and breast cancers, do you know if we are talking Targretin or Panretin? Also will you be putting together a complete report on the presentation and breakout for the thread?

To: Flagrante Delictu who wrote (13517)	1/20/1998 12:18:00 PM
From: Henry Niman	Respond to of 32384

Arvind Desai was just on CNBC. He's a Biotech analyst (I missed who he is currently with, but he used to be with Mehta & Isaly) and he expects the AHP - SBH deal to go through. He says both companies want it to happen and the new company would have 5.79% of market share (Pharmaceutical sales). They would pass Novartis (4.44%) and GLX (4.43%). He wasn't sure about terms and price. He said that AHP's current net income was 33% higher than SBH. He wasn't sure about regulatory concerns, especially in the US. He thought that there could very well be more rounds of consolidation. A leading market share of 5.79% still would be below most other industries. When asked about WLA, he said that diabetes and cholesterol drugs were doing well and now market cap was possibly too high for a merger in the next year or two. He thought that PNU might be a good merger candidate because of low value (2.5 X sales) and current CEO is from AHP.